Dr. Asmaa Salah, Manager of postmarketing administration and follow up- PVGA at Egyptian Drug Authority (EDA), is distinguished leader of postmarketing pharmacovigilance activities with more than 10 years’ experience in national regulatory authority (EDA). Her work focuses continuous follow up of EDA authorized products postmarketing and ensuring positive risk benefit balance of these products through continuous evaluation of Real-World Evidences (RWE) generated postmarketing.

Postmarketing pharmacovigilance related activities include adverse event reporting and related assessment, safety signal management, periodic benefit risk evaluation reports assessment, routine risk management plans evaluation and emerging safety issues activities. Dr. Asmaa is co-founder of active surveillance function in the national pharmacovigilance center. A passionate advocate for medicinal products regulation, Dr. Asmaa regularly speaks at international conferences, sharing her insights on medicinal products’ safety.